Rujukan Valgansiklovir

  1. 1 2 "Valcyte® (valganciclovir hydrochloride)". Australian Product Information. MedAdvisor International Pty Ltd. Dicapai pada 2023-08-10.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 "Valcyte- valganciclovir tablet, film coated Valcyte- valganciclovir hydrochloride powder, for solution". DailyMed. U.S. National Library of Medicine. 9 August 2018. Dicapai pada 24 October 2020.
  3. 1 2 3 4 5 6 7 "Valganciclovir Hydrochloride". The American Society of Health-System Pharmacists. Diarkibkan daripada yang asal pada 29 November 2016. Dicapai pada 28 November 2016.
  4. ↑ Long SS, Pickering LK, Prober CG (2012). Principles and Practice of Pediatric Infectious Disease (dalam bahasa Inggeris). Elsevier Health Sciences. m/s. 1502. ISBN 978-1-4377-2702-9. Diarkibkan daripada yang asal pada 2016-11-29.
  5. ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  6. ↑ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
  7. ↑ "Generic Valcyte Availability". Drugs.com. Diarkibkan daripada yang asal pada 17 March 2017. Dicapai pada 25 June 2017.
  8. 1 2 "Valganciclovir: MedlinePlus Drug Information". MedlinePlus. U.S. National Library of Medicine. Diarkibkan daripada yang asal pada 2016-11-10. Dicapai pada 2016-11-10.
  9. ↑ "A Physiologically Based Pharmacokinetic Model for Ganciclovir and Its Prodrug Valganciclovir in Adults and Children". The AAPS Journal. 18 (6): 1453–1463. November 2016. doi:10.1208/s12248-016-9956-4. PMID 27450227.
  10. 1 2 3 4 "Antiviral activity and mechanism of action of ganciclovir". Reviews of Infectious Diseases. 10 (Suppl 3): S490–S494. 2016-08-01. doi:10.1093/clinids/10.supplement_3.s490. PMID 2847285.
  11. ↑ "Mechanism of ganciclovir-induced chain termination revealed by resistant viral polymerase mutants with reduced exonuclease activity". Proceedings of the National Academy of Sciences of the United States of America. 111 (49): 17462–17467. December 2014. Bibcode:2014PNAS..11117462C. doi:10.1073/pnas.1405981111. PMC 4267342. PMID 25422422.
  12. ↑ Vardanyan R, Hruby V (2016). "34: Antiviral Drugs". Synthesis of Best-Seller Drugs. m/s. 709–713. doi:10.1016/B978-0-12-411492-0.00034-1. ISBN 978-0-12-411492-0.
  13. ↑ "US Court rules Ranbaxy's generic valganciclovir does not infringe Roche's Valcyte patent" (PDF). Pharmabiz. 16 October 2009. Diarkibkan daripada yang asal (PDF) pada 2016-03-04.
  14. ↑ "First-Time Generic Drug Approvals". U.S. Food and Drug Administration. November 2014. Diarkibkan daripada yang asal pada 2014-11-16.
  15. ↑ "Valganciclovir". Drugs.com. Dicapai pada 23 October 2020.

Rujukan

WikiPedia: Valgansiklovir https://web.archive.org/web/20161129083300/https:/... https://web.archive.org/web/20161129144653/https:/... https://web.archive.org/web/20170317091653/https:/... https://web.archive.org/web/20161110112925/https:/... https://web.archive.org/web/20160304030554/http://... https://web.archive.org/web/20141116094145/https:/... https://www.drugs.com/monograph/valganciclovir-hyd... https://www.drugs.com/availability/generic-valcyte... https://www.drugs.com/international/valganciclovir... https://books.google.com/books?id=nQ7-o8JAH7kC&pg=...